Ironwood Pharmaceuticals (IRWD) saw its stock soar 28% on Friday following AbbVie's (ABBV) announcement of better-than-expected sales for Linzess (linaclotide). The irritable bowel syndrome medication generated $315 million in U.S. sales during the third quarter, significantly surpassing the $244 million anticipated by analysts. This represents a 39.6% increase compared to the previous year. Ironwood had previously projected U.S. sales for Linzess to reach between $800 million and $850 million by 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.